Overview

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Status:
Active, not recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This is a Phase Ib study to evaluate the safety and preliminary anti-tumor activity of pembrolizumab in combination with pemetrexed with or without oxaliplatin in patients with chemo-refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without any further standard treatment options.

Phase:

Phase 1

Details

Lead Sponsor:

NSABP Foundation Inc

Collaborators:

Eli Lilly and Company
Merck Sharp & Dohme Corp.

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate
Folic Acid
Hydroxocobalamin
Oxaliplatin
Pembrolizumab
Pemetrexed
Vitamin B 12
Vitamin B Complex
Vitamins